5 results for “Cancer-Clinic Suppression Claims”
Claims that COVID vaccination causes sudden aggressive cancers at population scale.
Claims that clinics, regulators, or pharmaceutical companies suppress alternative cancer cures.
GLP-1 receptor agonists (semaglutide/Ozempic/Wegovy, tirzepatide/Mounjaro) are the fastest-growing drug class of the 2020s. Real adverse event reports exist in FDA FAERS data — including thyroid concerns, pancreatitis, and suicidal ideation reports — and are publicly available. Large peer-reviewed clinical trials (NEJM SELECT 2023, SURMOUNT-1 2022) have found these side effects either absent at statistically significant levels or outweighed by cardiovascular benefit. The conspiracy claim that pharma is deliberately hiding life-threatening side effects contradicts the publicly available clinical-trial data and FDA post-market surveillance, which are accessible to any researcher.
Two opposing suppression narratives circulate about pediatric gender-affirming care. The first holds that established, evidence-based care is being suppressed by transphobic state legislation (partially supported: more than 20 US states have enacted restrictions or bans since 2021). The second holds that the evidence base for pediatric transition interventions is itself weaker than advocacy bodies have claimed, and that clinicians and medical associations have suppressed this uncertainty (partially supported: the UK's independent Cass Review, published April 2024, found the evidence base "remarkably weak" and recommended a more cautious, individualized approach). This is a contested, ongoing medical-evidence debate with real factual stakes on multiple sides.
Claims circulate that pharmaceutical companies or medical institutions suppress Repatha (evolocumab, a PCSK9 inhibitor approved by the FDA in 2015) or effective alternatives to statins. The claim has no documentary basis. Repatha is FDA-approved, actively marketed by Amgen, and available by prescription in more than 60 countries. Its limited uptake relative to statins reflects cost, insurance coverage, and prescribing guidelines — not suppression. Statins remain the first-line standard of care because they are proven, inexpensive, and widely effective; PCSK9 inhibitors are used as second-line or add-on therapy for high-risk patients who cannot tolerate or do not respond adequately to statins.